Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer. Li B, Jiang C, Xu Y, Fan X, et al. BMC Cancer 2022;22:828.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li B, Jiang C, Xu Y, Fan X, et al. Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer. BMC Cancer 2022;22:828.
PMID: 35906610